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Abstract
Background: Warfarin therapy is effective for the prevention of stroke in patients with atrial
fibrillation. However, warfarin therapy is underutilized even among ideal anticoagulation
candidates. The purpose of this study was to examine the use of warfarin in both inpatients and
outpatients with atrial fibrillation within a Veterans Affairs (VA) hospital system.
Methods: This retrospective medical record review included outpatients and inpatients with atrial
fibrillation. The outpatient cohort included all patients seen in the outpatient clinics of the VA
Connecticut Healthcare System during June 2000 with a diagnosis of atrial fibrillation. The inpatient
cohort included all patients discharged from the VA Connecticut Healthcare System West Haven
Medical Center with a diagnosis of atrial fibrillation during October 1999 – March 2000. The
outcome measure was the rate of warfarin prescription in patients with atrial fibrillation.
Results: A total of 538 outpatients had a diagnosis of atrial fibrillation and 73 of these had a
documented contraindication to anticoagulation. Among the 465 eligible outpatients, 455 (98%)
were prescribed warfarin. For the inpatients, a total of 212 individual patients were discharged with
a diagnosis of atrial fibrillation and 97 were not eligible for warfarin therapy. Among the 115 eligible
inpatients, 106 (92%) were discharged on warfarin.
Conclusions: Ideal anticoagulation candidates with atrial fibrillation are being prescribed warfarin
at very high rates within one VA system, in both the inpatient and outpatient settings; we found
warfarin use within our VA was much higher than that observed for Medicare beneficiaries in our
state.
Background
Warfarin therapy is highly effective for the prevention of
ischaemic stroke in atrial fibrillation [1]. Despite the
accepted benefit of warfarin therapy, several reports have
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indicated that warfarin therapy is underutilized even in
ideal anticoagulation candidates with atrial fibrillation.
Most studies have reported rates of use between 13–60%
[2-8]. For example, a national study of inpatient Medicare
beneficiaries with atrial fibrillation demonstrated that
approximately 55% of patients were discharged on warfa-
rin [9].
Many of the previous studies about the use of warfarin in
atrial fibrillation have focused on the prescription of war-
farin on discharge from an acute hospitalization. Since
some patients may be discharged from the hospital with a
plan to begin warfarin therapy as an outpatient, these
prior studies may have underestimated the use of warfarin
for patients with atrial fibrillation. The Veterans Affairs
(VA) Healthcare System is a useful setting for studying the
use of warfarin therapy in both the inpatient and outpa-
tient arenas because the electronic medical record con-
tains prescription medication data as well as the inpatient
and outpatient medical records (including progress notes,
laboratory data, radiology reports, and other consult
reports).
The objective of this study was to examine the use of war-
farin in both inpatients and outpatients with atrial fibril-
lation within a VA setting. Specifically, we used the same
methodology as the Medicare Health Care Quality
Improvement Program's National Stroke Project – Atrial
Fibrillation [10], so that we could compare rates of warfa-
rin use in ideal anticoagulation candidates with atrial
fibrillation from one VA system to those in the private
sector.
Methods
We assembled two retrospective cohorts of patients to
evaluate both inpatients and outpatients with atrial fibril-
lation. The medical records of both the inpatients and the
outpatients were reviewed to confirm the diagnosis of
atrial fibrillation, to identify any exclusion criteria, and to
determine if patients were being prescribed warfarin.
Diagnosis of atrial fibrillation
Using the criteria developed by the Medicare Health Care
Quality Improvement Program's National Stroke Project –
Atrial Fibrillation [10], a physician's documentation of
the diagnosis of atrial fibrillation was required for inclu-
sion (electrocardiogram data were not used to make the
diagnosis of atrial fibrillation). For the outpatients, Physi-
cians' Current Procedural Terminology (CPT) codes were
used to identify potential patients with a diagnosis of
atrial fibrillation. For the inpatients, the International
Classification of Diseases, 9th Revision, Clinical Modifi-
cation (ICD-9-CM) discharge diagnosis code (427.31)
was used to identify potential patients with a diagnosis of
atrial fibrillation. Chart review was used to confirm the
diagnosis for both the inpatients and the outpatients; a
physician's documentation of atrial fibrillation in a
progress note, a consult note, the discharge summary, or
the problem list was needed for confirmation.
Medical record abstraction was conducted by two of the
authors (KR, SK) using standard definitions. All of the
exclusions were reviewed by three of the authors (KR, SK,
DMB), a sample of the charts of patients with an exclusion
criteria was re-abstracted (DMB), and any disagreements
were resolved by consensus.
Cohort descriptions
The outpatient cohort included all of the patients seen in
the outpatient clinics of the VA Connecticut Health Care
System during the month of June 2000 with a diagnosis of
atrial fibrillation. Outpatient clinics include both primary
care and subspecialty clinics. Some of these clinics have a
particular interest in the care of patients with atrial fibril-
lation such as cardiology and anti-coagulation clinics,
however, most of the clinics do not have such a special
interest (e.g., mental health, physical therapy, dermatol-
ogy, endocrinology).
The inpatient cohort included all patients discharged
from the VA Connecticut Health Care System West Haven
Campus with any discharge diagnosis of atrial fibrillation
(primary or secondary diagnosis) during the period of
October 1, 1999 through March 31, 2000. Some of the
patients in the inpatient cohort were readmitted during
our study period; this report includes data from individ-
ual patients for their first hospital stay.
Exclusion criteria
The Medicare Health Care Quality Improvement Pro-
gram's National Stroke Project – Atrial Fibrillation project
developed a set of exclusion criteria to identify ideal can-
didates for warfarin therapy; we used this exclusion crite-
ria for the current study. Patients were excluded if they
met one or more of the following: current sinus rhythm;
bleeding disorder; endocarditis or pericarditis (within 6
months); seizures; intracranial hemorrhage; intracranial
surgery or biopsy; lone atrial fibrillation; dual chamber
pacemaker; alcohol or drug abuse; allergy to warfarin;
hepatic failure; schizophrenia or active psychotic disorder;
comfort care or terminal illness with life expectancy less
than 6 months; un-repaired intracranial aneurysm; exten-
sive metastatic cancer; brain cancer; malignant hyperten-
sion; peptic ulcer disease; hemorrhage; documentation
that the patient refused warfarin therapy; prior complica-
tion or allergy related to past use of warfarin; or physician
documentation of a rationale for not prescribing warfarin,
including risk for bleeding, risk for falls, mental status
impairment, liver disease, arthritis requiring non-steroi-
dal anti-inflammatory medications or aspirin, pendingBMC Cardiovascular Disorders 2004, 4:18 http://www.biomedcentral.com/1471-2261/4/18
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surgery or other invasive procedure, terminal illness,
patient's inability to obtain necessary blood work, or his-
tory of patient's non-adherence to warfarin [10]. Patients
in intermittent or paroxysmal atrial fibrillation were
included in the study, however, patients who were noted
to be in current sinus rhythm and for whom atrial fibrilla-
tion was not a current problem were not included. For
example, a patient with atrial fibrillation in the setting of
an acute myocardial infarction or post-coronary bypass
grafting for whom the atrial fibrillation was not a current
medical problem was not included.
Warfarin prescription
For all of the patients, warfarin prescription was deter-
mined from the medical record. Patients receiving warfa-
rin from the VA pharmacy were readily identified from the
VA pharmacy component of the medical record. Patients
receiving warfarin privately were identified from the
progress notes. For inpatients, warfarin prescription was
evaluated at the time of discharge from the hospital. For
outpatients, warfarin prescription was evaluated at the
time of examination of the medical record. Each outpa-
tient medical record was examined in detail to determine
the presence or absence of warfarin prescription. For those
outpatients patients in whom this determination was dif-
ficult or if the data collector had a question about the
patient, then the medical record was examined again by
three of the authors to determine the presence or absence
of warfarin prescription. This study received Institutional
Review Board approval.
Statistical analysis
Student's t-tests were used to compare dimensional varia-
bles, and Fisher Exact and chi-square tests were used to
assess binary variables. Two-sided p-values <0.05 were
considered to be statistically significant. Exact binomial
95% confidence interval were calculated for the propor-
tions of patients using warfarin in the inpatient and out-
patient cohorts. The SAS System software release 6.12
(Cary, N.C.) was used for data analysis.
Results
Outpatient cohort
A total of 538 patients from the VA Connecticut outpa-
tient clinics were identified as having a diagnosis of atrial
fibrillation (age: 74.0 years mean ± 8.3 standard devia-
tion; 529 [98%] men). Of these, 73 patients had one or
more contraindication to anticoagulation (Table 1). Of
the 465 eligible patients, 455 (98%; 95%CI 96–99%)
were prescribed warfarin.
Table 1: Exclusion Criteria*
Characteristic Inpatients Outpatients
N = 212 N = 538
N (%)† N (%)†
Sinus rhythm 32 (15) 42 (8)
Death 21 (10) 1 (0.2)
History of gastrointestinal hemorrhage 18 (8) 6 (1)
Fall risk 14 (7) 4 (0.7)
Pacemaker 4 (2) 9 (2)
Lone atrial fibrillation 4 (2) 1 (0.2)
Terminal illness 4 (2) 0 (0)
Patient refused 3 (1) 6 (1)
History of intracranial hemorrhage 3 (1) 3 (0.6)
Transfer to outside facility 3 (1) 0 (0)
Multi-infarct dementia in comfort care patients 2 (0.9) 0 (0)
Warfarin held for procedure or surgery 2 (0.9) 0 (0)
Warfarin allergy 1 (0.5) 0 (0)
Failed to comply with warfarin protocol, 
warfarin stopped
1 (0.5) 1 (0.2)
History of seizures 1 (0.5) 0 (0)
Elective admission to begin sotalol and 
discontinue warfarin
1 (0.5) 0 (0)
Previous bleeding on warfarin 0 (0) 1 (0.2)
*These exclusion criteria were taken directly from the Medicare Health Care Quality Improvement Program's National Stroke Project – Atrial 
Fibrillation.10
†Note: some patients had more than one reason for not being prescribed warfarin.BMC Cardiovascular Disorders 2004, 4:18 http://www.biomedcentral.com/1471-2261/4/18
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The ten patients who were not prescribed warfarin did not
differ from those who received warfarin with respect to
age (mean age ± standard deviation; no warfarin: 76.6 ±
11.5, warfarin: 73.9 ± 8.1; p = 0.3). Among the ten
patients who were not prescribed warfarin: one was a dial-
ysis patient who received his medical care primarily from
private physicians outside of the VA, he was eventually
placed on warfarin; the medical record of one 90-years-
old patient, who also received the majority of his health
care from private physicians, indicated that his private
physician had elected not to prescribe anticoagulation
"because of age"; one patient had a history of alcohol use;
and in the remaining 7 patients there was no documenta-
tion of a reason for why the warfarin had not been pre-
scribed (3 of the 7 patients were receiving the majority of
their medical care outside of the VA).
Inpatient cohort
A total of 212 individual patients were discharged with a
diagnosis of atrial fibrillation (age: 72.9 years mean ± 9.9
standard deviation; 211 [99.5%] males). During the
admission these 212 patients, 17 died during their hospi-
talization, 3 were transferred to a facility outside of the VA
Connecticut Healthcare System, and 77 had one or more
contraindication to anticoagulation. Of the 115 remain-
ing eligible patients, 106 (92%; 95%CI 86–96%) were
discharged on warfarin.
The nine patients who were not prescribed warfarin did
not differ from those who were prescribed warfarin with
respect to age (mean age ± standard deviation; no warfa-
rin: 76.4 ± 7.4, warfarin: 72.6 ± 7.9; p = 0.2). To determine
if some of the eligible inpatients who were not discharged
on warfarin later received warfarin in the outpatient set-
ting, we examined the outpatient records of the nine inpa-
tients who were not discharged on warfarin: 5 died; 3 no
longer receive care at our medical center (and no medica-
tion data were available); and for 1 patient, the medical
record stated that he was offered warfarin therapy but that
he refused to accept it. Similarly, we evaluated a sample of
50 eligible patients who had been discharged on warfarin
therapy and examined their warfarin use post-discharge: 7
no longer receive care at our medical center (and no med-
ication data are available); 4 were taken off of warfarin (3
because they were cardioverted as outpatients, and for 1
patient the warfarin was discontinued after an episode of
bright red blood per rectum); and 2 patients have died.
Among the eligible inpatients 12/115 (10%) had history
of prior stroke or transient ischemic attacks; 3/12 (25%)
were not prescribed warfarin on discharge. No reasons
were documented for why these patients were not given
warfarin.
Unique patients
There was overlap between the inpatient and outpatient
cohorts such that a total of 722 unique patients were iden-
tified among the 212 inpatients and the 538 outpatients.
Discussion
We found high rates of warfarin prescription in ideal anti-
coagulation candidates with atrial fibrillation treated
within this VA system. A total of 561 of 580 ideal antico-
agulation candidates (97%) were prescribed warfarin:
98% of ideal outpatient anticoagulation candidates and
92% of ideal inpatient anticoagulation candidates. These
rates of warfarin use for atrial fibrillation are substantially
higher than those reported previously from private sector
academic and community hospitals. For example, as part
of the Medicare Health Care Quality Improvement Pro-
gram's National Stroke Project – Atrial Fibrillation, medi-
cal records were reviewed from a random sample of
Medicare beneficiaries, hospitalized during the period
1998–1999, with any discharge diagnosis of atrial fibrilla-
tion from each state [9,10]. The exclusion criteria for the
Medicare medical record review were the same as those
used for the current study and were developed to select a
cohort of atrial fibrillation patients who were "ideal" can-
didates for oral anticoagulation because they do not have
any contraindications to oral anticoagulation [10]. There-
fore, one would expect that the rates of warfarin use
would be higher in ideal anticoagulation candidates than
in a general population of patients with atrial fibrillation.
Overall, the rate of warfarin prescription for ideal antico-
agulation candidates with atrial fibrillation patients by
state ranged from 31–65%, with a median of 55% in the
Medicare study [9]. In Connecticut, 57% of eligible atrial
fibrillation inpatients were discharged on warfarin [9].
Therefore, the inpatient rates observed in the current
study of 90–92% are much higher than those observed for
Medicare beneficiaries using similar methodology.
We report the anticoagulation rates from one VA health-
care system, and our findings may not be generalizable to
other VA healthcare systems or to non-VA hospitals. Spe-
cifically, our results may not be generalizable to women
with atrial fibrillation. Furthermore, given that the out-
patient cohort for this study was obtained from a one-
month sample, we may have selected patients who are
more likely to be seen at an out-patient clinic, and there-
fore, our findings may also have limited generalizability
to atrial fibrillation patients who do not require or who
do not have access to regular out-patient clinical care.
Although we have found higher rates of warfarin use than
most of the previous studies in this area [2-9], our find-
ings are similar to those reported by Gottlieb and Salem-
Schatz [11] who found that 78.8% of atrial fibrillation
patients in an HMO setting were receiving warfarin. Our
findings are also similar to those reported by Bradley et al.BMC Cardiovascular Disorders 2004, 4:18 http://www.biomedcentral.com/1471-2261/4/18
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from another VA health care system [12]. Bradley et al.
demonstrated that 89% of patients without a contraindi-
cation to anticoagulation were prescribed warfarin [12].
Several possible factors might account for the high use of
warfarin in VA hospitals. First, the actual rates of warfarin
prescription may be higher in VA facilities where anticoag-
ulation clinics are well established, the electronic medical
record ensures that all services (primary care and consult
services) have access to a patient's medical record, the staff
has academic affiliations, and the VA culture embraces
quality improvement and medical error reduction initia-
tives. Within the VA Connecticut Health Care System,
pharmacist-directed anticoagulation clinics are available
at two sites, in West Haven and Newington, Connecticut.
Veterans who choose to obtain warfarin from the VA phar-
macy are usually followed at one of these two anti-coagu-
lation clinics. Veterans can elect to purchase warfarin from
private pharmacies and have their anticoagulation inten-
sity monitored privately (usually by their private internist
or private cardiologist). Second, the higher rate may result
from data collection differences between studies. Specifi-
cally, given the comprehensive VA electronic medical
record, VA-based researchers may be able to identify more
contraindications for anticoagulation. No quality
improvement projects to increase the use of warfarin for
patients with atrial fibrillation in the VA Connecticut
Healthcare System were initiated during or immediately
prior to the study period. A limitation of the current study
is that we were unable to determine the specific reasons
for why such a high rate of warfarin use was observed.
The retrospective nature of this study permitted us to eval-
uate clinical practices without altering physicians' behav-
ior. However, this retrospective chart review may have
limitations. First, we may not have identified those
patients who are prescribed warfarin by private practition-
ers and obtain their warfarin from non-VA pharmacies.
This would result in even higher rates of warfarin prescrip-
tion than we have reported.
Second, we assembled our cohort using diagnosis codes
for atrial fibrillation and did not use electrocardiographic
data. Those patients who had atrial fibrillation by electro-
cardiogram, but who were not identified as having atrial
fibrillation by their clinicians, would not have been
included in this study. Because such patients are unlikely
to receive warfarin our estimates of warfarin use are higher
than would have been observed if we had used electrocar-
diography to identify atrial fibrillation patients. While
many studies of the use of warfarin for atrial fibrillation
have also assembled cohorts using diagnosis codes and
not electrocardiographic data, the VA-based study by Bra-
dley et al. used electrocardiographic criteria and their find-
ings are similar to ours [12].
Third, some may argue that we excluded patients who
would benefit from anticoagulation. For example,
patients with atrial fibrillation and numerous other risk
factors for stroke might benefit from anticoagulation
despite the presence of a contraindication to anticoagula-
tion such as a risk for falls. We chose to use the exclusion
criteria developed for the Medicare Health Care Quality
Improvement Program's National Stroke Project – Atrial
Fibrillation [10] so that we could compare the rates of
warfarin prescription observed within one VA system to
those seen for Medicare beneficiaries.
Fourth, this study includes a total of 722 unique patients.
Although some studies of warfarin use in patients with
atrial fibrillation have included similar numbers of
patients (e.g., N = 635 in the study of Medicare beneficiar-
ies with ischemic stroke and atrial fibrillation by Brass, et
al) [13], many studies have included much larger sample
sizes (e.g., N = 11,699 in the study of Medicare beneficiar-
ies with new-onset atrial fibrillation) [14]. Often, the
studies with the largest sample sizes were secondary anal-
yses of existing administrative datasets [14]. Future studies
should be directed at evaluating the use of oral anticoagu-
lation in veterans with atrial fibrillation using national VA
data where both large sample sizes and nationally repre-
sentative sampling are possible.
Conclusion
We conclude that high rates of adherence to treatment
guidelines regarding the use of anticoagulation in patients
with atrial fibrillation can be achieved. Our experience,
and that of Bradley et al., indicates that high rates of war-
farin use can be achieved across at least two VA settings
[12].
Competing interests
The authors declare that they have no competing interests.
All of the authors are employed by the VA Connecticut
Healthcare system. Dr. Bravata is supported by an
Advanced Research Career Development Award from the
Department of Veteran Affairs Health Services Research &
Development Service.
Authors' contributions
All of the authors contributed to this manuscript, partici-
pated in the research design and manuscript preparation.
Two of the authors (SK, KR) conduct the data collection.
Three of the authors (DMB, SK, KR) reviewed the data and
conducted the analyses.
References
1. Goldstein LB, Adams R, Becker K, Furberg CD, Gorelick PB, Hade-
menos G, Hill M, Howard G, Howard VJ, Jacobs B, Levine SR, Mosca
L, Sacco RL, Sherman DG, Wolf PA, del Zoppo GJ: Primary preven-
tion of ischemic stroke: A statement for healthcare profes-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cardiovascular Disorders 2004, 4:18 http://www.biomedcentral.com/1471-2261/4/18
Page 6 of 6
(page number not for citation purposes)
sionals from the Stroke Council of the American Heart
Association. Circulation 2001, 103:163-182.
2. Brass LM, Lichtman JH, Wang Y, Marciniak TA, Gurwitz JH, Radford
MJ, Krumholz HM: Intracranial hemorrhage associated with
thrombolytic therapy for elderly patients with acute myo-
cardial infarction: results from the Cooperative Cardiovas-
cular Project. Stroke 2000, 31(8):1802-11.
3. Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Cha-
chashvily S, Shteinshnaider M, Litvinjuk V, Modai D: Warfarin for
stroke prevention still underused in atrial fibrillation: pat-
terns of omission. Stroke 2000, 31:1217-1222.
4. Craig J, Goudie B: Which acute stroke patients with atrial
fibrillation are prescribed warfarin therapy? Results from
one-year's experience in Dundee. Scottish Medical Journal 2000,
45:110-112.
5. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE:
Warfarin use among ambulatory patients with nonvalvular
atrial fibrillation: the anticoagulation and risk factors in atrial
fibrillation (ATRIA) study.  Annals of Internal Medicine 1999,
131:927-934.
6. Leckey R, Phillips S: Atrial fibrillation and the use of warfarin in
patients admitted to an acute stroke unit. Canadian Journal of
Cardiology 2000, 16:481-485.
7. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM,
Bian J: Quality of anticoagulation management among
patients with atrial fibrillation: results of a review of medical
records from 2 communities. Arch Intern Med 2000, 160:967-973.
8. Smith NL, Psaty BM, Furberg CD, White R, Lima JA, Newman AB,
Manolio TA: Temporal trends in the use of anticoagulants
among older adults with atrial fibrillation. Arch Intern Med 1999,
159:1574-1578.
9. Jencks SF, Cuerdon T, Burwen DR, Fleming B, Houck PM, Kussmaul
AE, Nilasena DS, Ordin DL, Arday DR: Quality of Medical Care
Delivered to Medicare Beneficiaries: A Profile at State and
National Levels. JAMA 2000, 284:1670-1676.
10. Medicare Health Care Quality Improvement Program: Stroke Pre-
vention in Atrial Fibrillation.  [http://projects.ipro.org/shared/
admin_memos/hcqip/200207.pdf].
11. Gottlieb L, Salem-Schatz S: Anticoagulation in atrial fibrillation.
Does efficacy in clinical trials translate into effectiveness in
practice? Archives of Internal Medicine 1994, 154:1945-1953.
12. Bradley B, Perdue K, Tisdel K, Gilligan D: Frequency of anticoag-
ulation for atrial fibrillation and reasons for its non-use at a
veterans affairs medical center. Am J Cardiol 2000, 85:568-572.
13. Brass L, Krumholz H, Scinto J, Mathur D, Radford M: Warfarin use
following ischemic stroke among Medicare patients with
atrial fibrillation. Archives of Internal Medicine 1998, 158:2093-2100.
14. Johnston JA, Cluxton RJ Jr, Heaton PC, Guo JJ, Moomaw CJ, Eckman
MH:  Predictors of warfarin use among Ohio medicaid
patients with new-onset nonvalvular atrial fibrillation. Archives
of Internal Medicine 2003, 163:1705-10.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2261/4/18/prepub